-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SQLL+cJYJPi++bH7vuyKPnN2vlU9OLnce8j8yCWkiIZYBjznZqovl1v+9GiQq6WO K7mXm8504tt6R13l5ReI+Q== 0000950116-02-000064.txt : 20020414 0000950116-02-000064.hdr.sgml : 20020413 ACCESSION NUMBER: 0000950116-02-000064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020116 ITEM INFORMATION: Other events FILED AS OF DATE: 20020123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25169 FILM NUMBER: 02515287 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANA STATE: A1 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO M5J STATE: A1 8-K 1 eightk.txt 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2002 ---------------- Generex Biotechnology Corporation ------------------------------------------------------ (Exact name of registrant as specified in its charter) Delaware 000-25169 98-0178636 - ------------------------------ ------------ ----------------- (State or other (Commission (IRS Employer jurisdiction of Incorporation) File Number) Identification No.) 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J 2G2 ------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 416/364-2551 --------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events. On January 16, 2002, Generex Biotechnology Corporation (the "Company") announced that it successfully completed a proof of concept, Phase I clinical study of morphine delivery using the Company's proprietary buccal delivery technology. The study indicates that the bioavailability of buccal morphine is comparable to intra-muscular injection and significantly superior to immediate release oral morphine tablets. In addition, the study indicates that buccally-delivered morphine provides significantly faster onset of action than immediate release oral morphine tablets. The Company also announced that in light of the results of the study, the Company and Elan Corporation, plc have expanded their business venture to include buccal morphine for the management of pain and have designated buccal morphine as the initial product for development under Generex (Bermuda) Ltd. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEREX BIOTECHNOLOGY CORPORATION Dated: January 23, 2002 By: /s/ E. Mark Perri --------------------- ------------------------------- E. Mark Perri, Chairman and CFO -----END PRIVACY-ENHANCED MESSAGE-----